drugset / Trial / NCT07172126
Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
NaSingle-groupOpen-labelTreatment
Summary
TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker. The phase I phase of this trial aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3201 tablets for the treatment of advanced prostate cancer.
Timeline
- Start
- 2025-09
- Primary completion
- 2027-04
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB3201 | Other / unclassified | 25 mg | Oral |
| Subject | TQB3201 | Other / unclassified | 50 mg | Oral |
| Subject | TQB3201 | Other / unclassified | 100 mg | Oral |
| Subject | TQB3201 | Other / unclassified | 200 mg | Oral |
| Subject | TQB3201 | Other / unclassified | 400 mg | Oral |
| Subject | TQB3201 | Other / unclassified | 800 mg | Oral |
| Subject | TQB3201 | Other / unclassified | 1200 mg | Oral |